A sensitive LC-MS/MS method for the quantitation of oxycodone, noroxycodone, 6α-oxycodol, 6β-oxycodol, oxymorphone, and noroxymorphone in human blood

Truver, Michael T; Jakobsson, Gerd; Chermá, Maria D.; Swortwood, Madeleine J.; Gréen, Henrik; Kronstrand, Robert

doi:10.1016/j.jchromb.2021.122625

Cited by 3 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our method detected both OXY and IS at about 3.0 min. A total run time is 4 min, which is approximately 1 min shorter than that in previous reports 25,26 . Moreover, the volume of eluent (500 μl) during SPE in our method was also less than those (2000–3000 μl) in previous reports, 26,27 which could contribute to reduce the time required for drying the eluents.…”

Section: Discussionmentioning

confidence: 59%

“…A total run time is 4 min, which is approximately 1 min shorter than that in previous reports. 25,26 Moreover, the volume of eluent (500 μl) during SPE in our method was also less than those (2000-3000 μl) in previous reports, 26,27 which could contribute to reduce the time required for drying the eluents. Additionally, the amount of plasma used in our method is 100 μl, which is relatively smaller than that in previous reports (500-1000 μl) 26,29 except one 21 although the range of standard curve is almost similar to that in these reports.…”

Section: Discussionmentioning

confidence: 68%

“…Several methods have already been established to measure plasma concentrations of OXY using LC–MS/MS. There are several reports to simultaneously quantify the metabolites of OXY 25,26 . OXY is mainly metabolized to noroxycodone, the major metabolite, by N‐demethylation by CYP3A4/5 and to oxymorphone by O‐demethylation by CYP2D6.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Establishment to measure oxycodone in plasma with liquid chromatography–tandem mass spectrometry

Ito

Mori

Matsuo

et al. 2022

Neuropsychopharm Rep

View full text Add to dashboard Cite

Oxycodone (OXY) is classified as a “strong opioid” in the World Health Organization system of cancer pain treatment. However, OXY also causes severe adverse reactions, such as respiratory depression. Thus, in order to adjust the dosage of OXY for well‐managed pain relief with less toxicity, we tried establishing and validating a system for measuring plasma concentrations of OXY using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Human pooled plasma samples containing OXY diluted with 0.1% formic acid solution and internal standard (papaverine) were used for solid‐phase extraction. The eluents were injected into LC–MS/MS with Unison UK‐Silica column (100 × 2 mm, 3 μm, Imtakt). Mobile phase was a mixture of 1 mM ammonium formate solution and acetonitrile containing 0.1% formic acid (50:50). OXY in plasma could be measurable with good linearity in a concentration range of 2–100 ng/ml by using 100 μl of plasma within 4 min. Relative standard deviations of all validation results were within ±15%. These results suggest that our established method using LC–MS/MS to measure OXY in plasma would be useful to adjust the dosage of OXY in order to obtain its efficacy and to avoid its adverse reactions.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 68%

See 1 more Smart Citation

Establishment to measure oxycodone in plasma with liquid chromatography–tandem mass spectrometry

Ito

Mori

Matsuo

et al. 2022

Neuropsychopharm Rep

View full text Add to dashboard Cite

show abstract

“…Conjugation by uridine diphosphate glucuronosyltransferases (UGT) 2B7 occurs for oxymorphone and noroxymorphone to form the phase II metabolites oxymorphone-3β-D-glucuronide and noroxymorphone-3β-Dglucuronide, respectively. Circulating analytes found in blood after oxycodone administration are primarily oxycodone and noroxycodone (35). In urine, oxycodone and noroxycodone are the main analytes found together with oxymorphone-3β-D-glucuronide (36).…”

Section: Pharmacokineticsmentioning

confidence: 99%

“…Pharmacokinetic studies in the living have shown that the metabolite to parent drug ratio many times changes over time as a result of metabolism producing metabolites and eliminating parent drugs (33,35,128). It has earlier been suggested that metabolic ratios for oxycodone could be used to determine if death occurred shortly after administration pointing towards an acute intoxication (17).…”

Section: Interpretation Of Oxycodone Concentration Ratios (Paper I An...mentioning

confidence: 99%

Oxycodone in Forensic Toxicology : Analytical Strategies and Interpretation

Jakobsson

2022

Linköping University Medical Dissertations

Self Cite

View full text Add to dashboard Cite

A rapid and sensitive LC–MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone

Hulskotte,

Wilbrink‐Pijffers,

Arbouw

et al. 2024

Biomedical Chromatography

View full text Add to dashboard Cite

A sensitive and reliable LC–MS/MS method was developed and validated for the quantification of oxycodone and metabolites in human plasma. The method has a runtime of 6 min and a sensitivity of 0.1 μg/L for all analytes. Sample preparation consisted of protein precipitation. Separation was performed on a Kinetix biphenyl column (2.1 × 100 mm, 1.7 μm), using ammonium formate 5 mm in 0.1% aqueous formic acid and methanol LC–MS grade 100% in gradient elution at a flow rate of 0.4 ml/min. Detection was performed in multiple reaction monitoring mode using positive electrospray ionization. The method was linear over the calibration range of 0.1–25.0 μg/L for oxycodone, noroxycodone and noroxymorphone and 0.1–5.0 μg/L for oxymorphone. The method demonstrated good performance in terms of intra‐ and interday accuracy (86.5–110.3%) and precision (CV 1.7–9.3%). The criteria for the matrix effect were met (CV < 15%) except for noroxymorphone, for which an additional method was applied to compensate for the matrix effect. Whole blood samples were stable for 4 h at room temperature. Plasma samples were stable for 24 h at room temperature and 3 months at −20°C. Furthermore, the method was successfully applied in a pharmacokinetic drug interaction study of oxycodone and enzalutamide in patients with prostate cancer.

show abstract

A sensitive LC-MS/MS method for the quantitation of oxycodone, noroxycodone, 6α-oxycodol, 6β-oxycodol, oxymorphone, and noroxymorphone in human blood

Cited by 3 publications

References 9 publications

Establishment to measure oxycodone in plasma with liquid chromatography–tandem mass spectrometry

Establishment to measure oxycodone in plasma with liquid chromatography–tandem mass spectrometry

Oxycodone in Forensic Toxicology : Analytical Strategies and Interpretation

A rapid and sensitive LC–MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone

Contact Info

Product

Resources

About